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A B S T R A C T
The VirtualToxLab is an in silico technology for estimating the toxic potential—endocrine and metabolic
disruption, some aspects of carcinogenicity and cardiotoxicity—of drugs, chemicals and natural products.
The technology is based on an automated protocol that simulates and quantiﬁes the binding of small
molecules towards a series of currently 16 proteins, known or suspected to trigger adverse effects:
10 nuclear receptors (androgen, estrogen a, estrogen b, glucocorticoid, liver X, mineralocorticoid,
peroxisome proliferator-activated receptor g, progesterone, thyroid a, thyroid b), four members of the
cytochrome P450 enzyme family (1A2, 2C9, 2D6, 3A4), a cytosolic transcription factor (aryl hydrocarbon
receptor) and a potassium ion channel (hERG). The toxic potential of a compound—its ability to trigger
adverse effects—is derived from its computed binding afﬁnities toward these very proteins: the
computationally demanding simulations are executed in client–server model on a Linux cluster of the
University of Basel. The graphical-user interface supports all computer platforms, allows building and
uploading molecular structures, inspecting and downloading the results and, most important,
rationalizing any prediction at the atomic level by interactively analyzing the binding mode of a
compound with its target protein(s) in real-time 3D. Access to the VirtualToxLab is available free of charge
for universities, governmental agencies, regulatory bodies and non-proﬁt organizations.
ã 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
In the light of the REACH (Registration, Evaluation, Authoriza-
tion and Restriction of Chemicals) initiative of the European Union,
computer-based approaches are explicitly sought after as they may
predict the toxicity of drugs and chemicals—both to avoid
unnecessary animal tests and to reduce the number of late-stage
failures in drug discovery & development. Adverse effects triggered
by small molecules are frequently associated with their binding to
so-called “off targets”—bioregulators involved in biosynthesis,
signal transduction, transport, storage, and metabolism. Among
others, those include nuclear receptors, enzymes of the cyto-
chrome P450 family and ion channels (Colborn et al., 1993; Dibb,
1995; Guillette et al., 1995; McLachlan and Arnold, 1996; Rihova,
1998; Fischer, 2000; Aronov, 2005; De Graaf et al., 2005; Crivori
and Poggesi, 2006).
In silico techniques for the prediction of toxicological endpoints
are extremely appealing because of their expeditious return of
results and inexpensiveness (Muster et al., 2008). Computational
approaches are typically based on human data and can be applied
to hypothetical compounds, which is of great relevance for drug
discovery—both ecological and economical. They can be classiﬁed
into expert systems, QSAR (quantitative structure–activity rela-
tionships), protein modeling and ADME (adsorption, distribution,
metabolism, excretion) modeling. A large body of both review and
research articles exists for these technologies (see, for example,
Cronin et al., 2003; Veith, 2004; Helma, 2005; Piclin et al., 2006;
Simon-Hettich et al., 2006; Amini et al., 2007; Aronov et al., 2007;
Bender et al., 2007; Custer et al., 2007; Ecker and Chiba, 2007;
Ekins, 2007; Seraﬁmova et al., 2007; Enoch et al., 2008; Kavlock
et al., 2008; Merlot, 2008; Pavan and Worth, 2008; Benfenati et al.,
2009; Green and Naven, 2009; Nigsch et al., 2009; Spreaﬁco et al.,
2009; Valerio, 2009; Rossato et al., 2010; Cronin and Madden,
2010; Bars et al., 2011; Vuorinen et al., 2013; Gupta et al., 2013;
Roncaglioni et al., 2013; Shah and Greene, 2014; Toropov et al.,
2014; Schilter et al., 2014; Singh and Gupta, 2014; Ekins, 2014).
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Computational assessment of a compound’s toxicity should
always be discussed along with its ADME properties as those deﬁne
the bioavailability—a prerequisite for triggering a molecular
mechanism leading a toxic effect. Only when quantitatively
combining all aspects, one might be in a position to predict a
toxic endpoint. Otherwise one should employ the term “toxic
potential”, implying that other conditions must be met in order for
an adverse effect to manifest itself.
Developing and validating a three-dimensional model is very
laborious but would seem to be necessary when the molecular
mechanism triggering the adverse or toxic effect occurs via a
multifaceted molecular mechanism. Skin irritation, for example,
might be safely described by the physicochemical properties of a
compound. On the other hand, a complex endpoint such as
endocrine disruption may not be explainable even by a larger
ensemble of molecular descriptors.
Fig. 1. Flow chart of the VirtualToxLab. *Software licensed from Schrödinger Inc., Portland, OR, **from the University of Minnesota and ***from the Biographics Laboratory 3R,
Basel. (For interpretation of the references to color in the text, the reader is referred to the web version of this article.)
Fig. 2. Directional force ﬁeld employed in Cheetah (Vedani and Huhta 1990; Rossato et al., 2010).
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Manifestations of toxicity are frequently mediated by regulato-
ry macromolecules such as enzymes, receptors, ion channels or
DNA. These targets represent complex and ﬂexible three-dimen-
sional entities that attempt to optimize their interaction with a
small molecule (e.g., a xenobiotic) by adapting their 3D conforma-
tion, a mechanism referred to as “induced ﬁt”. Protein-bound
solvent molecules are frequently involved in stabilizing small-
molecule ligands or, upon release to the “bulk solvent” contribute
favorably to the binding entropy. Accounting and quantifying these
effects belongs to the most challenging tasks in the computational
sciences.
In this account, we present the more recent developments of
the VirtualToxLab—most noticeably, the change from multi-
dimensional QSAR (mQSAR) to 4D Boltzmann scoring for
computing binding afﬁnities based on the three-dimensional
structure of protein–ligand complexes. By avoiding the training of
a model against a set of compounds with known effects (such as in
QSARs) but using an “ab initio” approach instead, the bias of a
prediction from any training set is removed as the changes in free
energy of ligand binding, DG, are computed by direct comparison
of a compound's “behavior” in aqueous solution (mimicking the
cytoplasm) with those at the target protein employing the same
directional force ﬁeld. Moreover, the risk of extrapolation—
occurring when attempting to predict properties of compounds
not truly represented in a QSAR’s training set—is purged. The new
protocol has been validated with a total of 1288 test compounds
and employed to estimate the toxic potential of more than
2500 drugs, chemicals and natural products. All results are posted
on http://www.virtualtoxlab.org. We explicitly invite all interested
non-proﬁt organizations to freely access/utilize the technology,
and share their results with the scientiﬁc community at http://
www.biograf.ch/data/projects/OpenVirtualToxLab.php.
2. Methods
The technology underlying the VirtualToxLab has recently been
described in great detail (Vedani et al., 2012). In this account, we
therefore focus on the most recent extensions and the freely
accessible platform—the OpenVirtualToxLab.
The ﬂow chart of the VirtualToxLab is shown in Fig. 1. The
technology consists of two distinct modules: the user interface
(light green) and the server backend (light blue) which communi-
cate through an SSH protocol. The user interface features an
embedded 3D viewer for inspecting both input (compounds to be
uploaded) and output structures (resulting protein–ligand com-
plexes) and a 3D model builder to readily generate the three-
dimensional structure of any small molecule of interest. In a ﬁrst
step (blue borders) the compound’s behavior in aqueous solution is
simulated. This includes the identiﬁcation of the protonation and
tautomeric state at physiological pH (software Epik: Schrödinger,
2012), conformational sampling in (implicit) aqueous solution
(software MacroModel: Schrödinger, 2012), calculation of atomic
partial charges, both the solvent-accessible and polar surface area
(software AMSOL: Cramer and Truhlar, 1992) as well as the
simulation and quantiﬁcation of the compound’s interactions with
explicit solvent (in 50  50  50 Å water box: software Aquarius, cf.
Fig. 3). The second and central step (green borders) consists in the
identiﬁcation of the compound’s potential binding mode(s) by
simulating its 3D interaction with the protein (pharmacophore-
based pre-alignment: software Alignator/Dolina: Smieško, 2013;
Fig. 3. 4D-Boltzmann sampling as employed in the VirtualToxLab. Left: a compound’s (here: genistein) representations in aqueous solution (software Aquarius, Biographics
Laboratory 3R, 2013). The ligand–solvent interactions are quantiﬁed using a directional force ﬁeld (Vedani and Huhta, 1990; Rossato et al., 2010) and Boltzmann weighted to
obtain the interaction energy of the 4D ensemble. Right: sampling (software Alignator and Cheetah) and quantifying (software BzScore4D) of a ligand’s representation(s) at the
binding site of the target protein. The images were generated with the BioX software (Dobler, 2012).
Fig. 4. Comparison of experimental (horizontal axis) and predicted binding
afﬁnities (vertical axis) as obtained with the VirtualToxLab 5.0 featuring the novel
4D-Boltzmann scoring function. The solid diagonal line corresponds to a perfect
prediction, i.e., pKcalc = pKexp.1 The dashed lines mark predictions 1.0 log unit (a
factor 10) off the experimental value, the dotted lines 2.0 log units (a factor 100).
706 of the 1288 compounds (55%) are predicted within one, 1082 (84%) within two,
and 1232 (96%) within three orders of magnitude from the experiment. The
individual target proteins included 140 (AhR), 104 (AR), 106 (ERa), 96 (ERb), 110
(GR), 50 (hERG), 52 (LXR), 48 (MR), 95 (PPARg), 91 (PR), 82 (TRa), 82 (TRb), 52
(1A2), 85 (2C9), 55 (2D6) and 40 (3A4) test compounds, respectively.
1pK = –log (K).
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full Monte-Carlo sampling: software Cheetah: Rossato et al., 2010;
Vedani et al., 2012). The last step (red borders) comprises the
quantiﬁcation of the individual binding afﬁnities (software
BzScore4D) and the estimation of the toxic potential therefrom
(Vedani et al., 2012). These pieces of information—along with the
3D structures of all protein–ligand complexes—are then made
available to the client via the user interface. All relevant data can be
downloaded and stored locally and, most important, removed
completely from the server. The VirtualToxLab servers (currently
featuring 512 cores) are hosted by the University of Basel and
located in a physically and electronically safe environment.
The ﬂexible-docking protocol employed in Alignator and
Cheetah aims at identifying all potential binding modes at the
target protein, thereby speciﬁcally allowing for induced ﬁt and
dynamic solvation (Vedani et al., 2012). The underlying force ﬁeld
features directional terms for hydrogen bonds and metal–ligand
interactions, allows for metal–ligand charge transfer and includes
polarization terms (cf. Fig. 2; Vedani and Huhta, 1990; Rossato
et al., 2010). During the conformational sampling of a small
molecule in the binding pocket of a protein, a total of 6000
(optionally: 12,000 in double-sampling mode) different binding
poses are generated at each of the 16 currently employed proteins,
Table 1
Calculation of the toxic potential for bisphenol A following Eqs. (1)–(3).
Target Calculated afﬁnity  e.s.d. (M) (VirtualToxLab) TPnormalized (Eq. (1)) we.s.d. TPindividual (Eq. (2))
AR 4.6  107 1.6  107 0.326 0.957 0.311
AhR 3.0  105 1.2 105 0.189 0.949 0.180
CYP 1A2 2.3 105 1.0  105 0.198 0.944 0.187
CYP 2C9 3.5 105 1.6  105 0.185 0.943 0.174
CYP 2D6 4.0  105 1.7  105 0.179 0.948 0.170
CYP 3A4 1.8  104 7.6  105 0.131 0.947 0.124
ERa 8.0  106 2.6  106 0.232 0.958 0.223
ERb 5.4 108 1.6  108 0.395 0.964 0.381
GR 1.3  106 5.0  107 0.292 0.951 0.278
hERG 1.0  105 4.4 106 0.225 0.945 0.213
LXR 5.4 105 2.4 105 0.170 0.945 0.161
MR 1.4 106 5.7  107 0.289 0.950 0.274
PPARg 7.1 106 3.0  106 0.236 0.947 0.224
PR 1.5 106 6.2  107 0.286 0.949 0.272
TRa 1.7  105 6.0  106 0.208 0.956 0.199
TRb 9.7  106 4.1 106 0.226 0.947 0.214
Overall toxic potential = 0.484 (Eq. (3); range from 0.0 to 1.0); main target = ERb.
Fig. 5. Graphical user-interface of the VirtualToxLab. The embedded 3D viewer/model builder allow designing, submitting and analyzing any compound of interest. The
models are displayed in real-time 3D (cf. http://www.biograf.ch/data/projects/mechanism.php) which allows verifying any prediction by inspecting the binding mode at the
target protein(s) with atomic resolution. All images are generated with the embedded viewer or builder.
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120 (240) thereof fully minimized and 12 (24) each are retained for
the quantiﬁcation of the binding energy (Vedani et al., 2012). This
protocol is computationally demanding and results in 20–80 h of
CPU time for the estimation of the toxic potential of a single
compound. Our Linux cluster currently hosts 512 cores, allowing
for an average process rate of 300–400 compounds per day.
The sampling protocol has been previously described (Rossato
et al., 2010; Vedani et al., 2012). The calculation of the associated
binding afﬁnity, however, has been completely redesigned. While
the previously employed mQSAR technology (the 6D-QSAR
software Quasar, cf. Vedani et al., 2000, 2005; Vedani and Dobler,
2002) represents the highest QSAR level, its predictive power is—as
in principle for any such approach—limited to compounds at least
similar to the ensemble of ligands represented in the underlying
training set. For that reason, this algorithm was augmented by a
direct (force-ﬁeld based) estimation of the binding afﬁnity,
obtained from a molecule's identiﬁed binding modes at a
particular protein. While this enlarged the applicability range
for predictions, it still suffered from the problematic of deriving
reliable energy values from force-ﬁeld calculations. Particularly for
large and ﬂexible or highly charged ligands, this sometimes yielded
less accurate binding afﬁnities.
We therefore decided to employ a novel scheme by calculating
free energies of ligand binding, DG, from the difference in
interaction energies of a compound’s 4D representations in
aqueous solution (mimicking the cytoplasm) with those at the
target protein (Fig. 3). While binding afﬁnities derived with this
protocol may not reach the accuracy previously obtained through
mQSAR, the underlying protocol does not require the training of
any data. Instead, the binding energy (and, therefrom, the binding
afﬁnity) is obtained in an “ab initio”-type approach, solely
depending on the quality of the underlying force ﬁeld. This would
seem of utmost importance for our aim, as the compounds
submitted to the VirtualToxLab by third-party users are typically
not similar to any of those in the (previously employed) training
set.
In case of the phytoestrogen genistein binding to the estrogen
receptor b (cf. Fig. 3), the ligand–solvent interaction is computed to
15.1 kcal/mol for the sampled 25 low-energy conformers. At the
protein, the corresponding quantity yields 25.8 kcal/mol for the
Fig. 6. Binding of bisphenol A to the estrogen receptor b. In the 4D representation (stereo image; top panel) the individual poses are rendered employing Boltzmann-scaled
intensities, i.e., the higher its contribution to the binding afﬁnity the more prominent (i.e., the more opaque) it is depicted. The ligand is depicted in licorice mode, the protein
and the solvent by lines. The four individual binding modes (middle panel) disclose the details, e.g., the hydrogen bonds, which are represented as yellow, dashed lines. All
images were generated with the novel VTLViewer4D (Dobler, 2014). The bottom panel shows the experimental electron density map of bisphenol A bound to the estrogen
receptor a (PDB code = 3UU7, resolution = 2.2 Å). The experimental pose corresponds to pose 1 of our computed structures. The image was generated with the ASTEX viewer
(accessed through the PDB at http://www.rcsb.org).
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Fig. 8. Binding modes (4D ensembles) as identiﬁed by automated, ﬂexible docking (software Alignator and Cheetah). The protein is depicted as ribbons, the small molecules as
stick models colored by atom. (A) diethylstilbestrol bound to the estrogen receptor a; (B) genistein bound to the estrogen receptor b; (C) dexamethasone bound to the
glucocorticoid receptor; (D) progesterone bound to the progesterone receptor. For clarity, only the energetically most favorable poses are shown. The images were generated
with the BioX software (Dobler, 2012).
Fig. 7. Comparison of experimental (lime color) and predicted binding modes (colored by atom type) as obtained with the VirtualToxLab 5.0 employing the Alignator and Cheetah
software. Key hydrogen bonds are depicted as yellow, dashed lines. (A) diethylstilbestrol bound to the estrogen receptor a (PDB code: 2ERD, resolution = 2.0 Å); (B) genistein
bound to the estrogen receptor b (PDB code: 1QKM, resolution = 1.8 Å); (C) dexamethasone bound to the glucocorticoid receptor (PDB code: 1M2Z, resolution = 2.5 Å); (D)
progesterone bound to the progesterone receptor (PDB code: 1A28, resolution = 1.8 Å). The experimental structures lack hydrogen atoms, as they are typically not resolved in
protein structures determined by X-ray crystallography. Additional examples (for nuclear receptors) are given in Smieško (2013). All images were generated with the VMD
software (Humphrey et al., 1996). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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12 lowest-energy poses. The energy difference between those two
states, 10.7 kcal/mol, corresponds to a binding afﬁnity of
1.1 108M which is close to the experimental value of
1.2  108M. To challenge the technology, we have employed
1288 compounds—representing over 30 chemical classes—to test
the predictive power of our approach (Fig. 4). 706 of the
1288 compounds (55%) are predicted within one, 1082 (84%)
within two, and 1232 (96%) within three orders of magnitude from
the experiment. The predictive r2 is computed to 0.574, which
would seem to be moderate only, particularly when compared to
values previously obtained by mQSAR techniques for the very
16 target proteins where the individual predictive r2 ranged from
0.739 to 0.942 (Vedani et al., 2012; Vedani, 2014). In contrast
hereto, the binding afﬁnities in the most recent version of the
VirtualToxLab are no longer derived from trained models but,
instead, computed directly from the difference of a compound’s
interaction with the solvent and the target protein. Hence, they are
independent from any training set and may be safely applied to any
type of molecule, albeit with a slightly reduced predictive power
when compared to trained (e.g., QSAR) models. Of course, this
holds only for compounds similar to the (formerly) trained
ligands—for all other classes of molecules, only a direct scoring
approach may generate reliable predictions.
Compounds predicted too weakly (Fig. 4: points below the
diagonal) can be explained by the fact that our sampling protocol
(cf. above) is by no means exhaustive and that for this particular
case, the correct binding pose could not be identiﬁed. Most of these
compounds bind to proteins with large binding pockets, such as
hERG, LXR, PPARg and CYP3A4. On the other hand, compounds
predicted too strongly (Fig. 4: points above the diagonal) might
trigger an induced ﬁt that has been simulated but could not be
appropriately quantiﬁed. Other factors of uncertainty include
entropic effects and the quantiﬁcation of protein-bound solvent
released upon ligand binding. A ﬁnal source of inaccuracy may
stem from the sampling of a compound’s representations in
aqueous solution (software Aquarius). While currently the 25
energetically most favorable conformations (obtained from
conformational sampling employing an implicit solvent model;
software MacroModel), are optimized in explicit solvent, they may
not include all relevant representations. We modiﬁed the protocol
to include 100 conformers (requiring approximately 2–4 extra CPU
hours per compound) but, unfortunately, with only minimal
beneﬁt.
The philosophy underlying the VirtualToxLab is to estimate the
toxic potential of a compound through the normalized individual
binding afﬁnities towards a series of protein models known or
Fig. 9. ToxicityalertsasgeneratedbytheVirtualToxLab5.0.Thecompletelistingfor2665compoundsispostedathttp://www.biograf.ch/data/projects/virtualtoxlab_results.php.
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suspected to trigger adverse effects. The result is a value ranging
from 0.0 (none) to 1.0 (extreme), which may be interpreted as a
toxicity alert. In a ﬁrst step, the individual binding afﬁnities are
normalized for each individual target protein according to Eq. (1).
Next, the individual toxic potential, TPindividual, is calculated, again
for each individual target protein (Eq. (2)):
TPindividual ¼ affinitynormalized  weightstandard deviation (2)
with weightstandard deviation = 1.0–0.125  (standard deviation/afﬁn-
ity); standard deviation over the 12 (24) models and therein:
0.125 = 1/DpKmin,max (DpKmin,max = 8.0: afﬁnity range from
1.0  102M to 1.0  1010M).
Therefrom, the overall toxic potential (TPoverall) is determined
as follows: ﬁrst, the 16 TPindividual are ranked by their value. Then,
their contribution to the TPoverall is summed up according to Eq. (3).
TPoverall ¼
X16
n¼1
1:0  TPoverall;current
  TPindividual;n  Wsuper family
(3)
with wsuper family = 1.0/n (n: nth member of a super family).
To avoid substantial TPs resulting from high afﬁnities to
evolutionary similar protein targets (e.g., ERa and ERb), a
correcting weight, wsuper family, is applied. It decreases the
contribution for the nth member to the TP. Currently, ﬁve super
families are recognized: nuclear receptors I (AR, ERa, ERb, GR, MR,
PR), nuclear receptors II (LXR, PPARg, TRa, TRb), cytochrome
P450 enzymes (1A2, 2C9, 2D6, 3A4) and two singular families (AhR,
hERG).
Table 1 represents an extract from the log ﬁle and shows how
the toxic potential (TP) is calculated. From the normalized binding
afﬁnity (affnorm) using the weights reﬂecting the standard
deviation (we.s.d.), the individual toxic potential (TPind) is obtained
for each of the 16 target proteins. After ranking the contributions
and using Eq. (3), the overall TP is calculated. The example shows
how the toxic potential for bisphenol A (a polymer additive present
in many products of our daily life) is computed. The overall value of
0.484 suggests a moderate risk, particularly with respect to
binding to the estrogen receptor b. The VirtualToxLab estimates the
binding afﬁnity at 54 nM, which compares well with the
experimental value of 90 nM. Apart from the estrogen receptor
b, the compound would also seem to bind moderately to the
androgen receptor (460 nM), the glucocorticoid receptor (1.3 mM),
the mineralocorticoid receptor (1.4 mM), and the estrogen receptor
a (8.0 mM). The graphical-user interface allowing to up/download
data and to inspect/visualize results is 3D and 4D shown in Fig. 5.
Fig. 6 shows the 4D representation of bisphenol A binding to the
estrogen receptor b. The calculated binding afﬁnity of 54 nM
compares acceptably with the experimental value of 90 nM. The
most prominent pose contributes 79.2% to the binding afﬁnity, the
second one 13.1% with the remaining poses contributing 7.7%.
Multiple binding modes of small molecules binding to proteins
have also been experimentally identiﬁed (see, for example, Pineda-
Sanabria et al., 2011; Wang et al., 2013). This suggests that a 4D
representation might be preferred over a 3D approach. The
computational expense, although signiﬁcant, would seem to be
justiﬁed because the biologically relevant pose might be missed
when simply selecting the energetically most favorable binding
mode. Even experimental techniques (e.g., X-ray crystallography)
might not always identify the bioactive conformation, particularly
if the crystallization conditions (pH, buffer, temperature) are
different from those at the physiological state.
3. Results and discussion
Predicting the binding afﬁnity of a small molecule towards a
protein ﬁrst requires the binding mode being correctly and
accurately identiﬁed. To test our algorithm (cf. Vedani et al.,
2012; Rossato et al., 2010), we have applied the docking protocol
implemented in the VirtualToxLab (i.e., software Alignator and
Cheetah) to molecular systems for which the binding mode has
been identiﬁed by means of X-ray crystallography. Fig. 7 compares
the lowest-energy conformer as obtained through automated,
ﬂexible docking (software Alignator and Cheetah) with the
Fig. 10. Binding of tetrahydrogestrinone to the androgen receptor as identiﬁed through automated, ﬂexible docking (software Alignator and Cheetah). The ligand and key
amino-acid residues are depicted in licorice mode, the protein main-chain by cartoons and the inner surface (colored by depth). Protein-bound water molecules are shown as
blue beads. Hydrogen bonds are highlighted as yellow, dashed lines. The 3D (left/right stereo) representation allows for an optimal depth perception—particularly of the
protein cavities. The image was generated with the VMD software (Humphrey et al., 1996). (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
affinity > 1:0  102M ! affinitynorm ¼ 0:0
1:0  102M  1:0  1010M ! affinitynorm ¼
½logð1:0  102Þ  logðaffinityÞ
½logð1:0  1010Þ  logð1:0  102Þ
affinity < 1:0  1010M ! affinitynorm ¼ 1:0
)
(1)
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experimental X-ray crystal structure. While the rms agreement is
clearly within 1.0 Å (for B and D even within 0.5 Å), this is not
necessarily sufﬁcient for calculating the binding afﬁnity within a
factor of 10 (corresponding to 1.4 kcal/mol in a protein–ligand
complex featuring a total energy ranging form 5000 to 10,000 kcal/
mol) as the conformational ﬂexibility of the ligand at the binding
site is not accounted for. Such conformational and rotational
ﬂexibility has been veriﬁed, for example, through solution – NMR
techniques for M2WJ 332 binding to an artiﬁcial 13-base pair
construct (Wang et al., 2013).
In earlier accounts (Vedani et al., 2000, 2005; Vedani and
Dobler, 2002) we have demonstrated that a 4D representation
including all (Boltzmann weighted) feasible poses can provide
more accurate estimations of the associated binding afﬁnities.
Fig. 8 shows the corresponding 4D ensembles for the very
compounds: diethylstilbestrol bound to the estrogen receptor a,
genistein bound to the estrogen receptor b, dexamethasone bound
to the glucocorticoid receptor and progesterone bound to the
progesterone receptor. The individual poses are Boltzmann-
weighted, i.e., only the energetically most favorable binding
modes contribute signiﬁcantly to the binding energy.
Using the VirtualToxLab, we have estimated the toxic potential
(endocrine and metabolic disruption, some aspects of carcinoge-
nicity and cardiotoxicity) for over 2500 compounds—drugs,
chemicals and natural products—and posted the results on
http://www.virtualtoxlab.org. The aim of the technology is to
generate toxicity alerts, i.e., ranking the tested compounds in three
groups: toxic potential (TP)  0.3 (low), 0.3 < TP  0.6 (moderate)
TP > 0.6 (high). Fig. 9 shows the toxic potential for a selection of
compounds.
More informative than the toxic potential itself is the
underlying binding-energy proﬁle (cf. Table 1 for bisphenol A),
as it provides speciﬁc information at which target protein an
elevated binding afﬁnity—potentially triggering an adverse effect—
Fig. 11. Probing the kinetic stability of the danazol–androgen and estrogen receptor b complexes, respectively, by means of 5.0  109 s molecular-dynamics simulations. Top
panel: danazol binding to the androgen (left) and estrogen receptor b (right). The ligand is depicted licori-ce mode, the protein by lines, and hydrogen bonds are shown as yellow
dashed lines. The images were generated with the VMD software (Humphrey et al.,1996). Bottom panel: molecular-dynamical behavior of the protein–ligand complexes. The total
ligand–protein interaction energies (recorded at 1.0  1011 s intervals) are shown as thick lines (AR: blue, ERb: pink), those with key hydrogen bonds by thin lines. While the
thermodynamicbinding afﬁnity for the ARwould seemtobe inagreement withthe molecular-dynamics simulations, that forthe ERb is not,suggesting a bindingafﬁnity inthe mid
nM range. Details are given in the text. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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might be expected (cf. also the ﬁngerprinting display mode in
Fig. 5). The VirtualToxLab interface allows exporting the individual
binding afﬁnities into a csv ﬁle and, hence, to compute a
customized toxicity alert. Most important, our technology allows
rationalizing a given binding afﬁnity by inspection of the
associated protein–ligand complexes in real-time 3D using the
embedded 3D/4D viewer or, after exporting the coordinates in PDB
format, with any other software of choice. Fig. 10 shows the
computed binding mode of the anabolic steroid tetrahydrogestri-
none to the androgen receptor. The associated binding afﬁnity of
32 nM compares reasonably well with the experimental value of
8.5 nM.
As the docking and scoring algorithms within the VirtualToxLab
are based solely on thermodynamic considerations, it is suggested
to probe the kinetic stability of the protein–ligand complex of
interest by means of molecular-dynamical simulations. If the key
interactions (hydrogen bonds, salt bridges, binding to metal ions,
hydrophobic contacts) remain stable throughout a decent simula-
tion time (t  5.0  109 s), the “thermodynamic ﬁndings” may be
accepted; otherwise, the underlying afﬁnity and the associated
toxic potential must be reduced accordingly. Anabolic steroids, for
example, are expected to bind strongly to the androgen receptor,
but less signiﬁcantly to the estrogen receptors a and b. This was,
for example, found for stanozolol (AR = 6.1 nM, ERb = 350 nM,
corresponding to a selectivity factor of 57) but not for danazol (AR:
14 nM, ERb = 4.8 nM; selectivity factor < 1.0). We therefore simu-
lated the dynamic behavior of both the danazol–androgen and
estrogen receptor b complexes for 5.0  109 s each using the
Desmond software (Bowers et al., 2006) as implemented in the
VirtualDesignLab (Eid et al., 2013). The results are illustrated in
Fig. 11. For the danazol–androgen complex, the total ligand–
protein interaction energy (sampled at 1.0  1011 s intervals: blue
line) is varying between 37.5 and 54.3 kcal/mol (thick blue line),
the average being 47.8 kcal/mol. The key hydrogen bonds—
necessary to trigger an agonistic effect—with Asn705 (thin red line:
average energy = 5.5 kcal/mol), Thr877 (thin green line: 3.9
kcal/mol) and Arg752 (thin cyan line: 3.6 kcal/mol) are stable
throughout the entire simulation. In contrast hereto, the ligand–
protein interaction energy for the danazol–estrogen receptor b
complex varies between 24.6 and 41.6 kcal/mol (thick pink
line), the average being 33.6 kcal/mol. The key hydrogen bonds—
necessary to trigger an agonistic effect—with His475 (thin black
line: average energy = 0.4 kcal/mol), Glu305 (thin yellow line:
1.3 kcal/mol) and Arg346 (thin blue line: 0.1 kcal/mol) are never
really established throughout the entire simulation. This suggests
that the “kinetic” binding afﬁnity is signiﬁcantly lower (e.g., a factor
of 100) and the selectivity factor appropriate as expected.
A compound’s bioavailability is a prerequisite for its binding to a
target protein. Various molecular descriptors (e.g., lipophilicity,
solvent-accessible and polar surface areas, H-bond donors and
Fig.12. Bindingoftheperfumeodorant(R,R)-galaxolidetotheprogesteronereceptor.Theligandiscoloredbyatom,theprotein’smainchainrepresentedbyribbons.Thelipophilic
residuesliningthebindingpocketaredepictedbytheirvolume(yellowsurface).ThehydrogenbondtoGln725is indicatedayellow,dashedline.The3Dimagewasgeneratedwith
the VMD software (Humphrey et al., 1996). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig.13. Binding of the parent compound zearalenone (left) and one of its metabolites b-zearalanol (right) to the estrogen receptor b. The ligands and key amino-acid residues
are colored by atom, the inner protein surface by depth gradient. Hydrogen bonds are indicated as yellow dashed lines. While both compounds engage in a hydrogen bond
with Glu305 (visible at the bottom), b-zearalanol is additionally stabilized by a hydrogen bond with His475 (top right), resulting in a 28-fold increased computed binding
afﬁnity: 29 nM versus 820 nM. Both images were generated with the VMD software (Humphrey et al., 1996). (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
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acceptors, rotatable bonds, membrane permeability) have been
found to be closely associated with the oral (Lipinski, 2000; Veber
et al., 2002) as well as transdermal (Lian et al., 2008) availability of
a compound. Values for such descriptors may nowadays be readily
computed by freely available tools found in the Internet. The
binding of the perfume odorant galaxolide to the progesterone
receptor may serve as an example. The calculated binding afﬁnity
of 560 nM seems to be somewhat worrying. Visual inspection
(Fig. 12) justiﬁes the prediction as the binding mode shows a well-
deﬁned H-bond with the side-chain amide of Gln725 and the
hydrophobic portion of the molecule properly accommodated in
the lipophilic part of the binding pocket. The averaged computed
logP of galaxolide of 4.8  0.9 (software ALOGPS; Tetko and
Tanchuk, 2002) along with its low polar surface area (PSA < 10 Å2)
and absence of any rotatable bonds and H-bond donors suggests,
that galaxolide could be available in systemic circulation if ingested
or applied to the skin. The compound has been indeed detected in
the plasma of healthy young adults using body-lotion cosmetics in
concentrations up to 4.1 mg/L (Hutter et al., 2005). However, even
at such a concentration, galaxolide should not substantially
interfere with the endogenous ligand progesterone (Kexp = 3.7 nM,
Kcalc = 22 nM).
False-positive predictions may, thus, occur in all cases where
the kinetic stability of a protein–ligand complex is lower than the
thermodynamic and—probably more relevant—when the ADME
predisposition is unfavorable. We therefore plan to augment our
technology with a series of corresponding pre-ﬁlters in the near
future.
False-negative predictions may occur for at least three reasons.
Firstly (and most frequently), when the adverse effect of a
compound is triggered mechanisms other than those currently
tested in the VirtualToxLab. Examples include Ochratoxin A (OcA), a
well known mycotoxin which does not signiﬁcantly bind to any of
our target proteins and is associated with a toxic potential of
0.519 suggesting only a moderate toxicity. While the toxic
mechanism of OcA has not yet been fully disclosed (see, for
example, Sorrenti et al., 2013), a critical step of the toxic pathway is
the long residence time of OcA at the plasma protein serum
albumin. Secondly, a toxic response may be triggered by a
metabolite rather than by the parent compound. While our
technology does not automatically generate feasible metabolites
(several pieces of third-party software have been developed for
this very purpose), at least primary metabolites should always be
tested along with a parent compound. In an earlier study, we have
analyzed the activity of cyclo-diBA (a condensation product of
glycidyl ether and bisphenol A) metabolites—a compound that is
unintentionally formed as by-product during the coating of food
cans and, due to its lipophilic character, migrates from the epoxy
resin of the coating into the fatty tissues e.g., of canned ﬁsh
(Biedermann et al., 2013). Another example includes the metab-
olites of the mycotoxin zearalenone, which are known to display
estrogenic activity (see, for example, Takemura et al., 2007;
Metzler et al., 2010). While the VirtualToxLab suggests a toxic
potential of 0.409 for the parent compound, one of its metabolites,
b-zearalanol, is estimated at 0.504. Fig. 13 compares the identiﬁed
binding modes for the parent compound zearalenone and its
metabolite b-zearalanol. Another reason for a false-negative
Fig. 14. (A) Binding of E121 (citrus red 2) to the aryl hydrocarbon receptor; (B) DHCMT to the androgen receptor; (C) drospirenone to the progesterone receptor; (D) bisphenol
A to the estrogen receptor b. The ligands and key amino-acid residues are colored by atom, the inner protein surface by depth gradient. Hydrogen bonds are indicated as
yellow dashed lines. All images were generated with the VMD software (Humphrey et al.,1996). (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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prediction may lie in the fact that our sampling of the ligand at the
protein's binding site while extensive (cf. above) is not exhaustive.
Thus, the correct binding mode may simply not been have
generated within the 6000–12,000 trials. Finally, molecules that
trigger a substantial induced ﬁt (i.e., including changes in the
protein's main-chain conformation) are currently beyond our
computational time scale.
We have applied the VirtualToxLab technology to a series of
2564 compounds. The results are posted on http://www.virtual-
toxlab.org. Fig. 14 shows four selected examples. According to our
calculations, E121 (citrus red 2; a food dye, classiﬁed as class 2B
carcinogen) displays an afﬁnity of 420 nM towards the AhR, a
protein known to trigger chloracne and related diseases (see, for
example, Okey et al., 1994). The overall toxic potential is estimated
at 0.471, indicating a moderate risk at exposure or intoxication
(orange skins). Dehydrochloromethyltestosterone (DHCMT) has
been systematically applied to athletes in the former German
Democratic Republic with tragic consequences for some. The
VirtualToxLab calculates the binding afﬁnity of DHCMT toward the
AR to 11 nM and estimates the toxic potential to 0.545. In the past,
drospirenone, an oral contraceptive has frequently been in the
news. According to our simulations, it not only binds to the
progesterone receptor (36 nM) and the estrogen receptor b
(310 nM) but also to the GR (43 nM). The overall toxic potential
is estimated at 0.640, which should be deﬁnitely interpreted as a
toxic alert. Bisphenol A, a known endocrine disrupter would
mainly seem to bind to the estrogen receptor b (54 nM; exp. = 93
nM); substantial afﬁnities are also computed toward the GR
(1.3 mM) and the estrogen receptor a (8.0 mM). The overall toxic
potential is estimated to 0.484, suggesting a moderate risk,
particularly at prolonged exposure Table 2.
4. Conclusions
The VirtualToxLab—an in silico technology developed at the
Biographics Laboratory 3R, Basel—allows predicting the toxic
potential (endocrine and metabolic disruption, some aspects of
carcinogenicity and cardiotoxicity) of drugs, chemicals and natural
products. It is based on an automated protocol that simulates and
quantiﬁes the binding of any small molecule towards a series of
16 proteins known or suspected to trigger adverse effects: the
androgen, aryl hydrocarbon, estrogen a, estrogen b, glucocorti-
coid, hERG, liver X, mineralocorticoid, progesterone, thyroid a,
thyroid b and the peroxisome proliferator-activated receptor g as
well as the enzymes cytochrome P450 1A2, 2C9, 2D6 and 3A4. The
toxic potential is derived from the binding afﬁnities to these
16 target proteins, ranges from 0.0 (none) to 1.0 (extreme) and may
be interpreted as a toxic alert. The three-dimensional structure of
Table 2
Comparison of calculated and experimental binding afﬁnities for selected targets/compounds.
Target Compound Experimental afﬁnity (M) Calculated afﬁnity (M) Factor offa
AR Bisphenol A 7.5 105 3.9  108 19
DDT 1.8  105 1.7  106 10
Diethylstilbestrol 1.4 105 1.3  106 10
17b-Estradiol 4.1 107 6.0  108 5.8
Genistein 8.5 105 1.1 105 6.9
Tetrahydrogestrinone 8.4 109 3.2 108 2.8
ERa Bisphenol A 1.2  105 5.9  106 1.0
Coumestrol 1.0  107 5.7  108 0.7
Diethylstilbestrol 2.3  1010 9.7  109 41
17b-Estradiol 9.1 1010 3.7  108 40
Genistein 2.1 107 5.7  107 1.8
Kaempferol 3.1 106 4.2 107 6.3
ERb Bisphenol A 9.3  108 5.3 108 0.7
Coumestrol 2.5 108 9.7  109 1.6
Diethylstilbestrol 6.4 109 9.7  1010 5.5
17b-Estradiol 3.9  109 4.0  109 0.1
Ethinylestradiol 3.4 109 7.6  109 1.2
Genistein 1.2  108 1.1 108 0.1
AhR Benzo[a]anthracene 3.5 107 1.3  107 1.7
Benzo[a]pyrene 3.6  107 1.3  107 1.8
Dibenzo[ah]anthracene 1.6  108 9.1 108 4.7
TCDD 1.0  108 2.1 108 1.1
GR Dexamethasone 3.0  109 1.8  109 0.6
Prednisolone 3.2  108 4.1 109 6.7
hERG Astemizole 9.1 1010 1.6  108 17
Cisapride 5.6  107 1.9  106 2.3
LiverX Podocarpic acid benzyl ester 6.3  107 7.6  107 0.2
MR Dexamethasone 1.0  109 5.7  109 4.7
PPARg Farglitazar 1.2  109 4.0  1010 2.0
PR Progesterone 3.7  109 4.0  109 0.6
TRa Desamino-triiodo-L-thryoinine 5.6  109 6.4 1010 7.8
TRb Triiodo-L-thryoinine 9.3  1011 5.5 1010 4.9
1A2 1,4-Dichloronaphtaline 2.3  106 8.5 106 2.7
2C9 Losartan 8.1 106 6.8  106 0.2
2D6 Bupivacaine 7.8  107 2.7  106 2.5
3A4 Miconazole 4.8  107 4.9  107 0.1
a Deviation (factor off) = Kexp/kcalc 1.0 for Kexp > kcalc; factor = Kcalc/kexp 1.0 for Kexp< kcalc.
The “1.0” correction term is necessary, as for Kexp = kcalc, the ratio is 1.0 but the deviation 0.0.
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compounds to be tested can generated using the embedded model
builder or imported from external sources. The results can be
inspected in real-time 3D or downloaded (coordinates of the
protein–ligand complexes in PDB format) and analyzed by
third-party software. The graphical user interface supports all
major operating systems (Mac OS X, Linux, Windows). The
calculation of the toxic potential of a compound depends on its
size and conformational ﬂexibility. For a complete proﬁle (16 target
proteins), this typically requires 20–80 h on a single processor of a
Unix cluster of the University of Basel, which is currently capable to
process 300–400 compounds/day in total. The user can choose to
make his/her simulation results (i.e., afﬁnities, 3D binding modes,
toxic potentials) selectively visible to other users of the platform,
thus facilitating the dissemination of in silico toxicological results
of general interest. Emerging results and news on the technology
are continuously posted on http://www.virtualtoxlab.org. The
Open VirtualToxLab is freely accessible to universities, governmen-
tal or regulatory bodies, and non-proﬁt organizations. On-line
registration (and 3D viewer libraries) are available at http://www.
biograf.ch/data/projects/OpenVirtualToxLab.php.
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